---
id: ITE-2022-081
type: ITE
year: 2022
number: 81
created: 2025-08-08 07:54:57.698988
tags:
- ITE
- question
- ITE-2022
answer: C
topic: null
related_articles:
- title: Self-Monitoring of Blood Glucose in Patients With Non-Insulin-Dependent Diabetes
    Mellitus.
  path: 2023/2023-03-self-monitoring-of-blood-glucose-in-patients-with-non-insuli.md
  similarity: 0.833
  link: '[[2023/2023-03-self-monitoring-of-blood-glucose-in-patients-with-non-insuli|Self-Monitoring
    of Blood Glucose in Patients With Non-Insulin-Dependent Diabetes Mellitus.]]'
- title: 2023-05-index
  path: 2023/2023-05-index.md
  similarity: 0.8
  link: '[[2023/2023-05-index|2023-05-index]]'
- title: 'Should Metformin Continue as First-Line Pharmacotherapy for Patients With
    Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.'
  path: 2024/2024-03-should-metformin-continue-as-first-line-pharmacotherapy-for.md
  similarity: 0.8
  link: '[[2024/2024-03-should-metformin-continue-as-first-line-pharmacotherapy-for|Should
    Metformin Continue as First-Line Pharmacotherapy for Patients With Type 2 Diabetes?
    Yes: Metformin Is Still the Best Choice.]]'
- title: Metformin vs. Lifestyle Changes for Prevention of Type 2 Diabetes Mellitus.
  path: 2023/2023-04-metformin-vs-lifestyle-changes-for-prevention-of-type-2-diab.md
  similarity: 0.8
  link: '[[2023/2023-04-metformin-vs-lifestyle-changes-for-prevention-of-type-2-diab|Metformin
    vs. Lifestyle Changes for Prevention of Type 2 Diabetes Mellitus.]]'
- title: Metformin to Decrease Mortality in Patients With Prediabetes.
  path: 2025/2025-07-metformin-to-decrease-mortality-in-patients-with-prediabetes.md
  similarity: 0.667
  link: '[[2025/2025-07-metformin-to-decrease-mortality-in-patients-with-prediabetes|Metformin
    to Decrease Mortality in Patients With Prediabetes.]]'
topics:
- Endocrinology
- Hemoglobin A1C
- Type 2 Diabetes
related_articles_2023_2025:
- title: afp clinical answers
  path: 2023/12/2023-12-afp-clinical-answers.md
  similarity: 0.408
  link: '[[2023/12/2023-12-afp-clinical-answers|afp clinical answers]]'
- title: afp clinical answers
  path: 2024/08/2024-08-afp-clinical-answers.md
  similarity: 0.313
  link: '[[2024/08/2024-08-afp-clinical-answers|afp clinical answers]]'
- title: afp clinical answers
  path: 2024/01/2024-01-afp-clinical-answers.md
  similarity: 0.312
  link: '[[2024/01/2024-01-afp-clinical-answers|afp clinical answers]]'
- title: editorial xylazine overdose crisis
  path: 2023/09/2023-09-editorial-xylazine-overdose-crisis.md
  similarity: 0.311
  link: '[[2023/09/2023-09-editorial-xylazine-overdose-crisis|editorial xylazine overdose
    crisis]]'
- title: inside afp article of the year
  path: 2024/09/2024-09-inside-afp-article-of-the-year.md
  similarity: 0.31
  link: '[[2024/09/2024-09-inside-afp-article-of-the-year|inside afp article of the
    year]]'
last_updated: '2025-08-10T20:25:40.808419'
---

# Question ITE-2022-081

threshold of

## Options

**A.** 5.5%

**B.** 6.0%

**C.** 6.5%

**D.** 7.0%

**E.** 8.0%

## Answer

**C**

## Explanation

The diagnostic cutoff point for type 2 diabetes (see [[Articles/2023/2023-05-diabetes-management-primary-care.md|Diabetes Management in Primary Care: Evidence-Based Approaches]]) is a fasting plasma glucose level 126 mg/dL or a
hemoglobin A1c 6.5%. The diagnosis requires confirmation by repeat testing or by obtaining both a
fasting glucose level and hemoglobin A1c.
Ref: American Diabetes Association Professional Practice Committee: 9. Pharmacologic approaches to glycemic treatment:
Standards of Medical Care in Diabetes—2022 . Diabetes Care  2022;45(Suppl 1):S125-S143.



## Related Articles

- [[Articles/2023/2023-05-diabetes-management-primary-care.md|Diabetes Management in Primary Care: Evidence-Based Approaches]]

## References

*[To be added from answer key]*
